




Figure S1. Pathological liver changes in the control group and A groups on day 21 post-allogeneic bone marrow transplant (magnification, x200). Control, blank control group; A1 group, mild-moderate GVHD group; A2 group, mild-moderate GVHD group with CTLA-4 intraperitoneal injection; A3 group, mild-moderate GVHD group with TIRC7 intraperitoneal injection; A4 group, mild-moderate GVHD group with CTLA-4 and TIRC7 intraperitoneal co- injection. CTLA-4, cytotoxic T lymphocyte antigen-4; TIRC7, T-cell immune response cDNA 7.




Control group




A1 group



A2 group




A3 group




A4 group


Figure S2. Pathological liver changes in the control group and B groups on day 21 post-allogeneic bone marrow transplant (magnification, x200). Control, blank control group; B1 group, severe GVHD group; B2 group, severe GVHD group with CTLA-4 intraperitoneal injection; B3 group, severe GVHD group with TIRC7 intraperitoneal injection; B4 group, severe GVHD group with CTLA-4 and TIRC7 intraperitoneal co-injection. CLTA-4, cytotoxic T lymphocyte antigen-4; TIRC7, T-cell immune response cDNA 7.




Control group




B1 group



B2 group




B3 group




B4 group


Figure S3. Pathological lung changes in the control group and A groups on day 21 post-allogeneic bone marrow transplant (magnification, x200). Control, blank control group; A1 group, mild-moderate GVHD group; A2 group, mild-moderate GVHD group with CTLA-4 intraperitoneal injection; A3 group, mild-moderate GVHD group with TIRC7 intraperitoneal injection; A4 group, mild-moderate GVHD group with CTLA-4 and TIRC7 intraperitoneal co-injection. CTLA-4, cytotoxic T lymphocyte antigen-4; TIRC7, T-cell immune response cDNA 7.




Control group




A1 group



A2 group




A3 group




A4 group


Figure S4. Pathological lung changes in the control group and B groups on day 21 post-allogeneic bone marrow transplant (magnification, x200). Control, blank control group; B1 group, severe GVHD group; B2 group, severe GVHD group with CTLA-4 intraperitoneal injection; B3 group, severe GVHD group with TIRC7 intraperitoneal injection; B4 group, severe GVHD group with CTLA-4 and TIRC7 intraperitoneal co-injection. CLTA-4, cytotoxic T lymphocyte antigen-4; TIRC7, T-cell immune response cDNA 7.




Control group




B1 group



B2 group




B3 group




B4 group


Figure S5. Pathological colon changes in the control group and A groups on day 14 post-allogeneic bone marrow transplant (magnification, x200). Control, blank control group; A1 group, mild-moderate GVHD group; A2 group, mild-moderate GVHD group with CTLA-4 intraperitoneal injection; A3 group, mild-moderate GVHD group with TIRC7 intraperitoneal injection; A4 group, mild-moderate GVHD group with CTLA-4 and TIRC7 intraperitoneal co- injection. CLTA-4, cytotoxic T lymphocyte antigen-4; TIRC7, T-cell immune response cDNA 7.




Control group




A1 group



A2 group




A3 group




A4 group


Figure S6. Pathological colon changes in the control group and B groups on day 14 post-allogeneic bone marrow transplant (magnification, x200). Control, blank control group; B1 group, severe GVHD group; B2 group, severe GVHD group with CTLA-4 intraperitoneal injection; B3 group, severe GVHD group with TIRC7 intraperitoneal injection; B4 group, severe GVHD group with CTLA-4 and TIRC7 intraperitoneal co-injection. CLTA-4, cytotoxic T lymphocyte antigen-4; TIRC7, T-cell immune response cDNA 7.




Control group




B1 group



B2 group



B3 group



B4 group